All Posts

Summary Hedge fund holdings can help you discover new investment ideas We identified & follow the top biopharma-focused hedge funds Q3 hedge fund holdings reports were released on ~11/14/25 This report focuses on top holdings of top biopharma hedge funds as of 09/30/25 Top Biopharma Hedge Funds At BPIQ we identified the top smid-cap biopharma-focused hedge funds ^1. We updated our database of holding and other info re: these funds with their recently-released data for holdings

In this video we go over how to find and analyze biopharma stock catalyst events. Manny Vacchiano with the BiopharmIQ team goes over: - Identifying catalyst events - Finding data & information - Analyzing events and info Discover 100's of upcoming catalyst events on our biopharma research platform (free 30 day trial no cc required) : https://www.bpiq.com/ Catalyst events, biotech investing, stocks, due diligence, FDA, catalyst calendar, biopharm, biopharma, catalyst, biotech,

The team at Amp Bioresearch walks you through an initial look at a very basic starting point for biotech stock due diligence. Follow along as we uncover: - Company Discovery - Catalyst Analysis - Investment Thesis - An Example Check out the tools used in this video: https://www.bpiq.com/

This Amp educational QuickE walks through the 3 key risks that are related to an individual small or mid-cap biopharma company, that drive the share price of these companies. Every smid-cap biopharma investor should understand these risks as they devise their investment strategy. Find upcoming catalysts and read actionable DD: https://www.ampbioresearch.com/ Join our Biotech Investing group chat: https://www.discord.gg/K5qt7mE [This is not investment advice.]

This Amp educational QuickE walks through the 3 key risks that are related to an individual small or mid-cap biopharma company, that drive the share price of these companies. Every smid-cap biopharma investor should understand these risks as they devise their investment strategy. Find upcoming catalysts and read read actionable DD: https://www.ampbioresearch.com/ Join our Biotech Investing group chat: https://www.discord.gg/K5qt7mE [This is not investment advice.]

This education video is part of our AmpBioResearch.com intermediate biopharma investor educational program. It discusses a very important topic for anyone who invests in small and mid-cap biopharma companies: near-term dilution and the related topic, follow-on offerings. How can you tell if a dilution event that will likely decrease a stock price, is near? What is a good vs. bad follow-on offering? And related questions for biopharma invenstors.

Be "in the know" in the pending AMRN ANDA litigation alongside experienced PhD biotech patent attorney, Manny Vacchiano. Know when impactful events will occur; and understand their significance before, during and after they unfold. Subscribe today: https://bit.ly/2MHUdxZ

Experienced PhD biotech patent attorney and biopharma investor, Manny Vacchiano, discusses some key points and events in the appeal of the district court obviousness ruling of the AMRN ANDA litigation, and discusses the #1 misconception of investors with respect to the asserted patents.

The $AKRO $NVO M&A announcement earlier was a strong signal, check our post after the ETNB acquisition  for context. In addition, AKRO was in 4 of our 5 hedge fund favorite accounts. Deal Terms $54/share cash + $6/share CVR tied to FDA approval of efruxifermin (EFX) for MASH cirrhosis 57% premium to Akero’s pre-deal price Adds Phase 3 FGF21 analog EFX to Novo’s metabolic portfolio  FGF21 analogue EFX is the only treatment to show significant fibrosis regression in phase 2 in

The $AKRO $NVO M&A announcement earlier was a strong signal, check our post after the ETNB acquisition  for context. In addition, AKRO was in 4 of our 5 hedge fund favorite accounts.